Nuclease-dendrimer formulations for covid-19 and broad spectrum antiviral therapies and prophylaxis
In various embodiments, a composition in which a nuclease is formulated with a dendrimer is used, in a pharmaceutically effective dose, as a therapeutic agent for coronaviruses and broad spectrum viruses, such as HCoV-OC43, SARS-CoV-2 (covid-19). When cationized nuclease is mixed and/or compounded w...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | Chinese English |
Published |
28.07.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | In various embodiments, a composition in which a nuclease is formulated with a dendrimer is used, in a pharmaceutically effective dose, as a therapeutic agent for coronaviruses and broad spectrum viruses, such as HCoV-OC43, SARS-CoV-2 (covid-19). When cationized nuclease is mixed and/or compounded with dendrimers, an unexpected positive dendrimer effect appears. The positive dendritic macromolecule effect shows that the positive dendritic macromolecule is highly effective for catalyzing the antiviral RNA enzyme characteristic. In various embodiments, the composition of a cationized nuclease in combination with a dendrimer demonstrates such a synergistic amplification of the antiviral effectiveness and is used as a therapeutic agent against the coronavirus HCoV-OC43, SARS-CoV-2 and a broad spectrum of viruses in pharmaceutically effective doses. Example formulations that exhibit a positive dendritic effect are cationized RNAase A mixed and/or complexed with the second generation PAMAM dendrimers.
在各个实施例中,核酸酶与树 |
---|---|
AbstractList | In various embodiments, a composition in which a nuclease is formulated with a dendrimer is used, in a pharmaceutically effective dose, as a therapeutic agent for coronaviruses and broad spectrum viruses, such as HCoV-OC43, SARS-CoV-2 (covid-19). When cationized nuclease is mixed and/or compounded with dendrimers, an unexpected positive dendrimer effect appears. The positive dendritic macromolecule effect shows that the positive dendritic macromolecule is highly effective for catalyzing the antiviral RNA enzyme characteristic. In various embodiments, the composition of a cationized nuclease in combination with a dendrimer demonstrates such a synergistic amplification of the antiviral effectiveness and is used as a therapeutic agent against the coronavirus HCoV-OC43, SARS-CoV-2 and a broad spectrum of viruses in pharmaceutically effective doses. Example formulations that exhibit a positive dendritic effect are cationized RNAase A mixed and/or complexed with the second generation PAMAM dendrimers.
在各个实施例中,核酸酶与树 |
Author | SU XIN RUDIN LEONID IVANOVICH |
Author_xml | – fullname: RUDIN LEONID IVANOVICH – fullname: SU XIN |
BookMark | eNqNiksKwjAQQLPQhb87xAMUrKUWl1IUV125L2MypYE0E2bSorf3gwdw9XiPt1SzQAEXyjSj8QiCmcVg2Q3IuiMeRg_JUZCPaEOTs1l-1BCsvjOB1RLRJB6Hd0pucgxepx4ZokP5bpEp9k8PDydrNe_AC25-XKnt5XyrrxlGalEiGAyY2rrJ80O5q6p9cSr-eV4ed0Co |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | 用于COVID-19和广谱抗病毒疗法和预防的核酸酶-树枝状大分子调配物 |
ExternalDocumentID | CN116507723A |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_CN116507723A3 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 13:00:53 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | Chinese English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_CN116507723A3 |
Notes | Application Number: CN202180068571 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230728&DB=EPODOC&CC=CN&NR=116507723A |
ParticipantIDs | epo_espacenet_CN116507723A |
PublicationCentury | 2000 |
PublicationDate | 20230728 |
PublicationDateYYYYMMDD | 2023-07-28 |
PublicationDate_xml | – month: 07 year: 2023 text: 20230728 day: 28 |
PublicationDecade | 2020 |
PublicationYear | 2023 |
RelatedCompanies | FERRO LABS AB |
RelatedCompanies_xml | – name: FERRO LABS AB |
Score | 3.6190758 |
Snippet | In various embodiments, a composition in which a nuclease is formulated with a dendrimer is used, in a pharmaceutically effective dose, as a therapeutic agent... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE |
Title | Nuclease-dendrimer formulations for covid-19 and broad spectrum antiviral therapies and prophylaxis |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230728&DB=EPODOC&locale=&CC=CN&NR=116507723A |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NS8MwFH_MKepNp6LzgwjSW3E26Zodirh0Ywh2Q6bsNpKm4mR2o50o_vW-xM550VuSlpA-eF_p-_0ewIUOfE9zi1j2mi5TnLrKl5i4tthV8sRoyhJbIBs3ew_sduSPKvCyxMJYntB3S46IGpWgvi-svZ6vLrEiW1tZXKoJLs2uu8Mwcsrs2FQ1e9yJ2mFn0I_6whEiFLET34eGZaaBkSS9WYN1E0Ybnv3OY9ugUua_XUp3BzYGuFu22IXK53MNtsSy81oNNu_KH944LHWv2IMkNtTD6HRcNBXasPLnxEScZf-twkxIYnB17lWLyEwTlc-kJhZLmb-94pLpFJHLKfkGXWGObF9DG4qynsqPSbEP593OUPRcPO34RzRjEa8-jB5ANZtl6SEQ309pwBtJS2lUUiplwJmnfZmyIOA0VUdQ_3uf-n8Pj2HbiNncbnr8BKp4_vQU3fJCnVl5fgHOupL7 |
link.rule.ids | 230,309,786,891,25594,76906 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NT8IwFH9BNOJNUaP4NROz2yKsGyuHxUgHQYVBDBpupF1nxOAgG0bjX-9rHeJFb2vXNOtL3lf3fr8HcCE915ZUI5btuuUISizhckxcG04tenJI7ES6QDasdx6c25E7KsDLEgujeULfNTkialSE-r7Q9nq-usQKdG1ldikmODW7ag_9wMyzY1XVbFMzaPqtQT_oM5Mxn4VmeO8rlpkqRpLkeg3WPcXOq0Knx6ZCpcx_u5T2NmwMcLdksQOFz-cylNiy81oZNnv5D298zHUv24UoVNTD6HQsNBVSsfKnhoo48_5bmRoYkcLVWbWGwRNpiHTGpaGxlOnbK06pThEpnxrfoCvMkfUytKEo6yn_mGR7cN5uDVnHwq8d_4hmzMLVwcg-FJNZEh-A4box8Wg1agiJSko496hjS5fHjudREotDqPy9T-W_l2dQ6gx73XH3Jrw7gi0lcnXTadNjKOJZ4hN00QtxqmX7BdeMleg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Nuclease-dendrimer+formulations+for+covid-19+and+broad+spectrum+antiviral+therapies+and+prophylaxis&rft.inventor=RUDIN+LEONID+IVANOVICH&rft.inventor=SU+XIN&rft.date=2023-07-28&rft.externalDBID=A&rft.externalDocID=CN116507723A |